Genesis Digital Assets Breaks Ground on New 40MW Mining Data Center in Glasscock County...
Leading Multichain Payments Solution Utrust Announces Polygon Integration
Safety Training Seminars Offers CPR, BLS, ACLS, & PALS Training Courses in Sacramento, Woodland,...
HTC VIVE Partners With Imversed Enabling Avatars for Sake of Vtubers’ Economy
Thousands of metaverses have emerged a year after the world discovered the concept of the metaverse. Today, the avatar user experience in a metaverse is still far from that of gaming, in both movements and visualisations. Little breakthroughs have managed in the metaverse visual experience, however, in sight of the long-term growth of Web 3.0, avatars are looking to grow into capitalised money trees for users. An avatar will be able to have a fanbase, its own music and videos, its own ancillary products, and even have its rights commercially represented and managed. This requires levels of technical support that most metaverse systems are just not there yet.
HTC VIVE has brought some exciting breakthroughs in the part they play, integrating the latest avatar technology with Imversed quick release NFT technology. On top of this, VIVE recently upgraded the use of facial and motion tracking technologies to improve user experience, enabling avatars in metaverses to have body movements and facial expressions, intended to integrate interactive engagements with the immersion of reality with the virtual in an instant integrated interaction, so that avatars can behave like a real person would. Synchronized imaging technology that is used also gives avatars freedom to take photos and selfies anywhere anytime in any-verse. Trekking to outer space, other planets, deep sea, or show up in various movie scenes, and capture moments of virtual travel and track memories, even recording the travel journeys, then mixing or editing together the content to share on their social media platforms will become a norm. Avatars can grow influence by gaining followers and make hot new topics or trends like any current 2D influencer. There are already influencers and celebrities building up their virtual self making it into an intellectual property to profit from and its nowadays not uncommon to gossip about celebrities such as Bruce Willis using DeepFake.
Talks of avatars interacting with real humans in the real world, and even perform without time and space restrictions, can now be done by a person's endorsed avatar identity in Imversed XR-Land brought into reality by using AR tools via projections creating a new type of Vtuber, this is what we had seen in the past in many superhero movies. Imagine further, where Vtubers with fanbases using the Imversed XR-Land to NFT minting function to distribute NFT digital assets, will be rolling the dollars in whilst the user in flesh is asleep at night. Limitations of the interactions between virtual reality IPs and the reality are now gone as Vtubers can interact with their fans, and a larger Web 3.0 asset empire and a scaled revenue system can generate continual income.
In 2023, tech brands are wanting to be releasing AR glasses. If so, XR-Land technology will catapult in its value bringing the avatar economy to a whole new level. Much of this technology will be available for public demonstration from this November onwards making it the right time to get started particularly with Viverse, which is currently the biggest industry partner of Imversed XR-Land, and this partnership soon will join forces also with popular gaming companies. The joint ventures makes Viverse readily available now to create personalized avatars. People of all ages should be ready to take part in this new wave of revenue stream from a personalized avatar no matter where and which verse or universe they are in at in any point in time. Creating and owning an Avatar with its own story and generating a personalized income in the expanding metaverse economy is hot the new trendy way to enrich an integrated virtual in reality lifestyle.
Stay tuned for more news updates on VIVE and Imversed:
VIVE:
Website: https://www.vive.com
Discord: https://discord.com/invite/QAtV6xXT5t
Twitter: https://twitter.com/htcvive
Imversed:
Website: https://imversed.world
Discord: https://discord.gg/umaeRaGXD2
Twitter: https://twitter.com/imversedhub
PR Kit: https://bit.ly/3MJ0vvu
Contact Information:
Johnson Chiang
CEO of Edison's Co.
[email protected]
Press Release Service by Newswire.com
Original Source: HTC VIVE Partners With Imversed Enabling Avatars for Sake of Vtubers' Economy
Intend™ Announces Strategic Partnership With Exer Urgent Care Helping to Streamline and Simplify Patient...
Stirling CBD Products Help Competitive Powerlifter in Her Training and Recovery
After more than 20 years of lifting weights and seven years as a competitive powerlifter, Robyn Machado knows what is needed to stay in top shape, and Stirling CBD's line of products are her go-to aid for recovery and alleviating pain during training.
Machado, 36, was ranked in the top 10 worldwide in the 60-kilo class. Now competing in the 67.5-kilo class, she was recently ranked 15th in the world. Stirling CBD's Delta 8 Sleep gummies and Magnesium Balm are key elements of her training. The Delta 8 gummies help Machado stay calm and relaxed without any adverse effects, while the magnesium balm on joints and sore muscles helps alleviate pain and soreness and speed up the healing process.
"When it comes to training, keeping stress to a minimum is optimal, so I use the Magnesium Balm during the day, which helps with inflammation," said Machado. "But I also train at night, so Delta 8 Sleep Gummies are key in helping me wind down after a workout and to allow me to chill out and get a great night's sleep. A good night's sleep is critical to a powerlifter, and Stirling's gummies help me fall asleep and stay asleep. I wake up feeling refreshed and ready to go."
Machado regularly sees Dr. Matt Arthur at 919Spine, who recommended the Stirling CBD products and introduced her to Stirling CBD President Joe Kryszak. "I love Stirling's products. They have really had a positive impact on my training and recovery," she said. "I've tried similar products, but the levels of CBD were too inconsistent. With Stirling, I know I'm getting consistency and the highest-quality product available. They show third party certificates of analysis of each product right on their webpage, so I know exactly what is going into my body."
CBD Muscle Gel is another lotion that Machado is a big fan of. The Muscle Gel has capsaicin, camphor and menthol, which creates an invigorating cold-hot sensation that helps blood flow in the muscle and joints. In addition, the aloe vera, black pepper extract, and witch hazel ingredients combine for a great solution for pre- and post-workout.
Designed to help alleviate joint pain, Stirling's CBD lotions are among the most powerful lotions on the market. In addition, all of Stirling's CBD lotions, gels, and balms are non-GMO-produced, organic, THC-free, vegan, free from additives and chemicals, and are never tested on animals.
For more information, please visit https://www.stirlingcbdoil.com
Contact Information:
Mike Albanese
[email protected]
Related Images
Press Release Service by Newswire.com
Original Source: Stirling CBD Products Help Competitive Powerlifter in Her Training and Recovery
Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia...
NEW YORK - October 17, 2022 - (Newswire.com)
Two recent studies show that the novel Optejet® dispenser from Eyenovia, Inc., an ophthalmic pharmaceutical technology company, may be a more "human-centric" design than traditional eye droppers, which may make treatments for vision problems, including myopia, presbyopia and mydriasis, easier to deliver.
The investigational Optejet® dispenser administers ophthalmic solutions horizontally using the company's proprietary Microdose Array Print (MAP™) technology. The system has been shown to deliver accurate microdoses through a precision spray, dispensing medication with the push of a button, with no need to tilt the head back, and requires minimal hand-eye coordination.
Traditional eye drops can deliver four to five times larger volumes of medication than the human eye can hold, which can cause overdosing and drug waste. The Optejet® dispenser is designed to administer 1/5 the volume of solution compared to a traditional eyedropper, making doses less likely to spill or run onto the patient's face.
"Traditional eye drops typically overdose a patient's eye with medication and preservatives, which can lead to significant dose-related side effects," said Michael Rowe, CEO of Eyenovia. "Optejet® is proving to be easier to use and therefore may deliver the appropriate dose of medication to potentially decrease side effects."
One paper (Rathi, Scott, 2020) presented at the 2020 American Society of Cataract and Refractive Surgery reviewed multiple studies comparing the Optejet® dispenser with traditional eye droppers. In one study with the Optejet®, the researcher successfully administered 96% of doses on the first attempt, and 95% of patients successfully self-administered the doses on the first attempt as well. Another study found ophthalmic technicians successfully delivered doses on 83% of first attempts and were successful 99% of the time within two attempts.
A separate study conducted by Eyenovia (2021) monitored the six-month daily eye drop treatment compliance of 28 children ages 6 to 13 with pediatric progressive myopia. It found that nearly 90% of children using the Optejet® once-daily treatment successfully complied with their treatment regimen. This compares favorably to the 50% compliance rate for pediatric ophthalmic medications or the 59-69% range for adult topical ophthalmic drug users (Naito, 2018; see also Patel, 1995; Winfield, 1990; Matsui, 1997).
The unique delivery mechanism of the Optejet® has the potential to fundamentally change how people think about administering eye medication. Of 100 presbyopic patients between the ages of 40-55, four out of five said they would prefer using the investigational Optejet® device over traditional eye drops, according to a survey conducted by Eyenovia.
Optejet® has not been approved, cleared, or licensed by the U.S. Food and Drug Administration for use, and it is not commercially available in the United States. For more information about the Optejet® device, visit eyenovia.com.
About Eyenovia, Inc.
Eyenovia, Inc. is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit www.eyenovia.com.
Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.
Contact Information:
Norbert Lowe
Vice President, Commercial Operations
[email protected]
Buse Kayar
[email protected]
Press Release Service by Newswire.com
Original Source: Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams
Enlyt Health Strengthens Its Advisory Board With Appointment of Industry Expert Nick Patel
Georgia Podiatric Surgeons Perform Total Ankle Joint Replacement for End Stage Ankle Arthritis
